Provectus Biopharmaceuticals, Inc. (PVCT) stock
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Earnings
Provectus Biopharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Provectus Biopharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2016ended Sep 30, 2016 | Nov 10, 2016after the close | – | – | – | Filing |
| Q2 FY2016ended Jun 30, 2016 | Aug 9, 2016after the close | – | – | – | Filing |
| Q3 FY2015ended Sep 30, 2015 | Nov 5, 2015before the open | – | – | – | Filing |
| Q2 FY2015ended Jun 30, 2015 | Aug 6, 2015before the open | – | – | – | Filing |
| Q1 FY2015ended Mar 31, 2015 | May 7, 2015before the open | – | – | – | Filing |
| Q4 FY2014ended Dec 31, 2014 | Mar 12, 2015before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Provectus Biopharmaceuticals has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Provectus Biopharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Provectus Biopharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Update
- News
- News
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- News
- Update
See a number that looks wrong?